Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,027 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Epiglottitis-Like Symptoms of COVID-19 in the Omicron Wave.
Iijima H, Tomita K, Okamoto R, Ogimi C. Iijima H, et al. Indian J Pediatr. 2022 Sep 20:1-2. doi: 10.1007/s12098-022-04371-1. Online ahead of print. Indian J Pediatr. 2022. PMID: 36125612 Free PMC article. No abstract available.
Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M. Hiraoka A, et al. Among authors: iijima h. Oncology. 2022 Sep 14. doi: 10.1159/000526521. Online ahead of print. Oncology. 2022. PMID: 36103846
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hatanaka T, et al. Among authors: iijima h. Hepatol Int. 2022 Sep 9. doi: 10.1007/s12072-022-10406-8. Online ahead of print. Hepatol Int. 2022. PMID: 36076009
Diagnosis of hepatic steatosis based on ultrasound attenuation imaging is not influenced by liver fibrosis.
Yuri M, Nishimura T, Tada T, Yoshida M, Fujiwara A, Kawata S, Yoshihara K, Yoshioka R, Ota S, Nakano R, Yuri Y, Takashima T, Aizawa N, Ikeda N, Shiomi H, Ide YH, Enomoto H, Yasuhiro F, Yano H, Iijima H. Yuri M, et al. Among authors: iijima h. Hepatol Res. 2022 Aug 26. doi: 10.1111/hepr.13831. Online ahead of print. Hepatol Res. 2022. PMID: 36018852
A novel SAVE score to stratify decompensation risk in compensated advanced chronic liver disease: an international multicenter cohort study.
Liu C, Cao Z, Yan H, Wong YJ, Xie Q, Hirooka M, Enomoto H, Kim TH, Hanafy AS, Liu Y, Huang Y, Li X, Kang N, Koizumi Y, Hiasa Y, Nishimura T, Iijima H, Jung YK, Yim HJ, Guo Y, Zhang L, Ma J, Kumar M, Jindal A, Teh KB, Sarin SK, Qi X. Liu C, et al. Among authors: iijima h. Am J Gastroenterol. 2022 Jun 15. doi: 10.14309/ajg.0000000000001873. Online ahead of print. Am J Gastroenterol. 2022. PMID: 35973168
Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance.
Tada T, Kumada T, Matono T, Nakamura S, Sue M, Matsuo Y, Takatani M, Iijima H, Tanaka J. Tada T, et al. Among authors: iijima h. JGH Open. 2022 Jun 6;6(7):462-469. doi: 10.1002/jgh3.12774. eCollection 2022 Jul. JGH Open. 2022. PMID: 35822120 Free PMC article.
1,027 results